FCGR3A and acute myeloid leukemia: Next, we evaluated our dual mode of action hypothesis, whereby CD25 Mab treatment would lead to a direct cytotoxicity of CD25+ AML cells and depletion of immunosuppressive Tregs through FcR bearing effector cells, such as FcgRIIIa (CD16) expressing NK cells.